Products Categories
| CAS No.: | 63250-09-9 |
|---|---|
| Name: | 2,3-DINOR THROMBOXANE B2 |
| Molecular Structure: | |
|
|
|
| Formula: | C18H30 O6 |
| Molecular Weight: | 342.43 |
| Synonyms: | 3-Pentenoicacid, 5-[(2R,3S,4S,6R)-tetrahydro-4,6-dihydroxy-2-[(1E,3S)-3-hydroxy-1-octenyl]-2H-pyran-3-yl]-,(3Z)- (9CI); 3-Pentenoic acid,5-[tetrahydro-4,6-dihydroxy-2-(3-hydroxy-1-octenyl)-2H-pyran-3-yl]-, [2R-[2a(1E,3S*),3b(Z),4b,6a]]-; 2,3-Dinor-TXB2; 2,3-Dinorthromboxane B2; Dinorthromboxane B2 |
| Density: | 1.209g/cm3 |
| Boiling Point: | 566.9°C at 760 mmHg |
| Flash Point: | 199.5°C |
| PSA: | 107.22000 |
| LogP: | 1.98920 |
- 81281-59-67-Benzylideneaminotheophylline
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 73441-42-6METHYL-5-CHLORO-2,2-DIMETHYLVALERATE
- 68439-39-4Poly(oxy-1,2-ethanediyl), alpha-(2-ethylhexyl)-omega-hydroxy-,
- 852475-26-4MC1568
- 958254-66-51H-Imidazo[4,5-b]pyridine-2-carboxaldehyde, 1-methyl-, hydrochloride
- 99170-93-1N-Methyl-2-oxazolamine
- 717878-06-31-(4-fluorophenyl)-4-nitro-1H-imidazole
- 914458-26-7[5-(2-fluorophenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-Methanone
- 894852-01-87-BROMO-2,2-DIMETHYL-2H-PYRIDO[3,2-B][1,4]OXAZIN-3(4H)-ONE
- Total:14 Page 1 of 1 1
What can I do for you?
Get Best Price
Chemistry
Chemistry informtion about 2,3-Dinor Thromboxane B2 (CAS NO.63250-09-9) is:
IUPAC Name: (Z)-5-[(2r,4s,6r)-4,6-Dihydroxy-2-[(E,3s)-3-Hydroxyoct-1-Enyl]Oxan-3-Yl]Pent-3-Enoic Acid
Synonyms: 2,3-Dinor-Txb2 ; 2,3-Dinor Thromboxane B2 ; 9alpha,11,15s-Trihydroxy-2,3-Dinor-Thromba-5z,13e-Dien-1-Oic Acid ; (E)-5-[(2s,3s,4s)-4,6-Dihydroxy-2-[(E,3s)-3-Hydroxyoct-1-Enyl]Oxan-3-Yl]Pent-3-Enoic Acid ; (5z,13e,15s)-9α,11,15-Trihydroxy-2,3-Dinorthromboxa-5,13-Dien-1-Oic Acid
MF: C18H30O6
MW: 342.43
Density: 1.209 g/cm3
Flash Point: 199.5 °C
Boiling Point: 566.9 °C at 760 mmHg
Enthalpy of Vaporization: 97.78 kJ/mol
Vapour Pressure: 3.25E-15 mmHg at 25°C
Following is the molecular structure of 2,3-Dinor Thromboxane B2 (CAS NO.63250-09-9) is:
Specification
Quantitation of 2,3-Dinor Thromboxane B2 (CAS NO.63250-09-9) was performed by gas chromatography-mass spectrometry. Under normal conditions the urinary excretion of 2,3-dinor-TxB2 was relatively constant in the same individual from day to day but during a 24-hour period a somewhat higher excretion rate was found during the first few hours after awakening. A pronounced reduction of the urinary excretion of 2,3-dinor-TxB2 was found after oral administration of 500 mg of aspirin or 50 mg of indomethacin, while 500 mg of paracetamol did not affect the urinary excretion. Increased excretion of 2,3-dinor-TxB2 was found in normal pregnancies and in diseases such as diabetes mellitus and homocysteinuria in comparison to the urinary excretion in normal healthy subjects. We also report one case, where the urinary excretion of 2,3-dinor-TxB2 was increased for a short period following the first symptoms of a myocardial infarction and those data indicate that thromboxane A2 (TxA2) may be of pathophysiological importance in human myocardial infarction. The results strongly indicate that measurements of the urinary excretion of 2,3-dinor-TxB2 should be meaningful as a tool for investigation of the involvement of thromboxane in various pathophysiological processes in vivo in man.